Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd2914710.26442/SG29147ArticlesСтатьиResearch ArticleControl of cardiovascular risk in patients with diabetesУправление сердечно-сосудистыми рисками у больных сахарным диабетомZhernakovaYu VЖернаковаЮ В

д-р мед. наук, ст. науч. сотр. отд. координации и мониторинга научных программ ИКК им. А.Л.Мясникова ФГБУ РКНПК

juli001@mail.ruChazovaI EЧазоваИ Е

академик РАН, д-р мед. наук, проф., и.о. ген. дир. ФГБУ РКНПК, дир. ИКК им. А.Л.Мясникова, рук. отд. гипертонии ФГБУ РКНПК

c34h@yandex.ruA.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian FederationИнститут клинической кардиологии А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России15092016133VOL 13, NO3 (2016)ТОМ 13, №3 (2016)424709042020Copyright ©; 2016, Consilium MedicumCopyright ©; 2016, ООО "Консилиум Медикум"2016Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/29147

Prevalence of diabetes mellitus (DM) is a version of pandemic, in Russia as well, nowadays. Mortality of patients suffering from DM is associated with the development of macrovascular complications and successful prevention of these complications depends on the complex approach to identify and to correct all modifiable risk factors, included in risk indexes. According to many experts’ point of view, key moments in reducing the risk of cardiovascular complications in patients with DM are to achieve target blood pressure and target levels of lipid metabolism, including the application of non-drug therapies. However, the appearance of new data concerning the possibility of antihyperglycemic therapy, no doubt, will change our point of view on managing cardiovascular risk in patients with DM, in particular empagliflozin, which can influence on cardiovascular outcomes.

Распространенность сахарного диабета (СД) в настоящее время носит характер пандемии, в том числе и в России. Смертность больных СД напрямую связана с развитием макроваскулярных осложнений, успешная профилактика которых зависит от комплексного подхода к выявлению и коррекции всех модифицируемых факторов риска, включенных в индексы риска. По мнению большинства экспертов, ключевым моментом в снижении риска развития сердечно-сосудистых осложнений у пациентов с СД является достижение целевых цифр артериального давления и показателей липидного обмена, в том числе с использованием немедикаментозных методов лечения. Вместе с тем появление новых данных о возможностях сахароснижающей терапии, в частности эмпаглифлозина, влиять на сердечно-сосудистые исходы, несомненно, внесет коррективы в наше представление об управлении сердечно-сосудистыми рисками у пациентов с СД.

arterial hypertensiondiabetes mellitusrisk managementdyslipidemiaempagliflozinартериальная гипертензиясахарный диабетуправление рискамидислипидемияэмпаглифлозинInternational Diabetes Federation Diabetes Atlas Update 2015. Seventh edition. Online version of IDF Diabetes Atlas: www.diabetesatlas.orgДедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. Сахарный диабет. 2015; 3 (18): 5-22.The effect of intensive treatment of diabetes on the development and progression of long - term complications in insulin - dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.Effect of intensive blood - glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.Nathan D.M, Cleary P.A, Backlund J.Y et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.Holman R.R, Paul S.K, Bethel M.A, Matthews D.R, Neil H.A. 10-year follow - up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.Gaede P, Lund-Andersen H, Parving H.H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta - analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-8.Nilsson P.M, Cederholm J, Zethelius B.R et al. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press 2011; 20: 348-54.Morrish N.J et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): 14-21.Folsom A.R et al. Hyperglycemia and Stroke Mortality Diabetes Care 1999; 22: 1077-83.Diabetes U.K. Cardiovascular disease. www.diabetes.org.uk (accessed 19.04.07)Mogensen C.E. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003; 21: 25-30.Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.Sarwar N, Gao P, Seshasai S.R. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta - analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-22.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.Cushman W.C, Evans G.W, Byington R.P et al. Effects of intensive blood - pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.Patel A, Mac Mahon S, Chalmers J et al. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.Holman R.R, Paul S.K, Bethel M.A et al. Long - term follow - up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-76.Tatti P, Pahor M, Byington R.P et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.Estacio R.O, Jeffers B.W, Hiatt W.R et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non - insulin - dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.Niskanen L, Hedner T, Hansson L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first - line therapy with an ACE inhibitor compared with a diuretic/beta - blocker - based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091-6.Lindholm L.H, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-5.Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369 (9557): 201-7.Pershadsingh H.A. New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator - activated receptor-γ. Drug Dev Res 2006; 67: 687-97.Derosa G et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin resistance, leptin and tumor necrosis factor - alpha. Hypertens Res 2006; 29: 849-56.Bakris G, Burgess E, Davidai G et al. Influence of glycemic control on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial (poster 0601-P). Presented at the 67th Scientific Sessions of the American Diabetes Association, 2007.The ONTARGETR Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваск. терапия и профилактика. 2014; 6 (13): 4-11.Sacks F.M, Pfeffer M.A, Moye L.A et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.Александров А.А. Статины и сахарный диабет: стабилизация «распадающихся» бляшек?//Consilium Medicum. 2003; 5 (9): 8-13.Mills E.J, O’Regan C, Eyawo O et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta - analysis of 40 000 patients. Eur Heart J 2011; 32: 1409-15.Baigent C, Keech A, Kearney P et al. Efficacy and safety of cholesterol - lowering treatment: prospective meta - analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.Kearney P, Blackwell L, Collins R, Keech A et al. Efficacy of cholesterol - lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta -analysis. Lancet 2008; 371: 117-25.Taskinen M.R, Adiels M, Westerbacka J et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 2011; 31: 2144-50.Barter P.J, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Eng J Med 2007; 357: 2109-22.Schwartz G.G, Olsson A.G, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Eng J Med 2012; 367: 2089-99.Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90.Sattar N, Preiss D, Murray H.M et al. Statins and risk of incident diabetes: a collaborative meta - analysis of randomized statin trials. Lancet 2010; 375: 735-42.Preiss D, Seshasai S.R, Welsh P et al. Risk of incident diabetes with intensive - dose compared with moderate - dose statin therapy: a meta - analysis. JAMA 2011; 305: 2556-64.Cannon C.P. Balancing the benefits of statins versus a new risk - diabetes. Lancet 2010; 375: 700-1.Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta - analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.Coutinho M, Gerstein H.C, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascularevents. Ametaregression analysis o fpublished data from 20 studies of 95,783 individuals followed for 12,4 years. Diabetes Care 1999; 22: 233-40.Turnbull F.M, Abraira C, Anderson R.J et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.Nathan David M. for the DCCT/EDIC Research group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care 2014; 37: 9-16.Stratton I.M, Adler A.I, Neil H.A et al. Association of glycaemiawith macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12.49Holman R.R, Paul S.K, Bethel M.A et al. 10-Year Follow - up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359: 1577-89.Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28.Meisinger C, Heier M, von Scheidt W et al. Gender - Specific short and long - term mortality in diabetic versus non diabetic patients with incident acute myocardial infarction inthereperfusionera(the MONICA/KORA Myocardial Infarction Registry). Am J Cardiol 2010; 106: 1680-4.